Finance

Lists
Q2 2026 earnings • released • EPS miss -11.54%
See results
EIKN:NASDAQ
Eikon Therapeutics Inc
$10.47
-5.25%
(-0.58) 1D
$10.47
0.00% (0.00)
After hours
Closed: Aug 17, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EIKN...
Open
$11.00
High
$11.03
Low
$10.31
Mkt. cap
567.11M
Avg. vol.
344.54K
Volume
415.02K
P/E ratio
0.57
52-wk high
$17.40
52-wk low
$7.90
EPS
$18.27
No. of employees
384
Open
$11.00
High
$11.03
Low
$10.31
Mkt. cap
567.11M
Avg. vol.
344.54K
Volume
415.02K
P/E ratio
0.57
52-wk high
$17.40
52-wk low
$7.90
EPS
$18.27
No. of employees
384
About Eikon Therapeutics Inc
CEO-
Employees384
Founded2019
HeadquartersMillbrae, California, United States
SectorBiotechnology
Websiteeikontx.com
Analyst ratings
Based on 3 analysts giving stock ratings to EIKN in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for EIKN in the last 3 months.
Highest
Current $10.47
$32.00 (+205.64%)
Average
$31.00 (+196.08%)
Lowest
$29.00 (+176.98%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Laaman
Morgan Stanley
Buy
Reiterated
$32.00
+205.6%
08/17/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
$29.00
+177%
08/17/2026
Jason Zemansky
Bank of America Securities
Buy
Reiterated
$32.00
+205.6%
06/03/2026
Robert Driscoll
Wedbush
Sell
Maintained
$5.00
-52.2%
05/12/2026
Joseph Catanzaro
Mizuho Securities
Buy
Initiated
$26.00
+148.3%
03/02/2026
Last report
Aug 13, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.63 / -$1.46
-11.54%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
66.19M
65.23M
70.05M
75.46M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19.14M
17.73M
17.29M
17.93M
Operating expense
85.33M
82.96M
87.34M
93.39M
Total operating expenses
85.33M
82.96M
87.34M
93.39M
Operating income
-85.33M
-82.96M
-87.34M
-93.39M
Other non operating income
-2.00K
-9.00K
-1.00K
-52.00K
EBT including unusual items
-105.21M
-79.66M
-82.96M
-88.41M
EBT excluding unusual items
-80.90M
-79.45M
-82.96M
-88.41M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-105.21M
-79.66M
-82.96M
-88.41M
Net profit margin
-
-
-
-
Earnings per share
-
-26.23
-2.46
-1.63
Interest and investment income
4.43M
3.52M
4.38M
5.04M
Interest expense
-
-
-
-
Net interest expenses
4.43M
3.52M
4.38M
5.04M
Depreciation and amortization charges
-
-
-
-
EBITDA
-81.12M
-77.57M
-82.12M
-88.26M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps